In comparison to SLC16A7 expression being associated with adverse outcomes in only lung adenocarcinoma (LUAD) and UCEC, there is added value in taking into account the genes in the SLC16A7 community-regulated cell cycle for more accurate predictions, thus improving the prognostic power for adverse outcomes in 10 cancers (e.g., kidney renal clear cell carcinoma (KIRC), LUAD, and UCEC) and favorable outcomes in two cancers (i.e., COAD and LUSC; Fig. 4c, d). This evidence concerns the gene SLC16A7 and lung adenocarcinoma.